Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.6
4.9
Journals
Marine Drugs
Special Issues
Bioactive Compounds from Marine Streptomyces (2nd Edition)
share announcement

Bioactive Compounds from Marine Streptomyces (2nd Edition)

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: closed (15 June 2024) | Viewed by 3213

Special Issue Editor

Prof. Dr. Jianhua Ju

E-Mail Website
Guest Editor
South China Seas Institute of Oceanography Chinese Academy of Sciences, Guangzhou, China
Interests: marine natural products; biosynthesis; marine microorganisms; anti-infective; antitumor
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Marine Streptomyces has emerged as an important resource for bioactive natural products due to their unique physiological and metabolic functions. The natural products derived from marine Streptomyces exhibit a variety of bioactive properties, especially in the antitumor and antibacterial areas, holding great promise for applications in the agricultural and pharmaceutical fields. Genetic manipulation technologies have also been applied in the search for new bioactive natural products from marine Streptomyces.

Given the success of the previous Special Issue “Bioactive Compounds from Marine Streptomyces, https://www.mdpi.com/journal/marinedrugs/special_issues/marine_Streptomyces", and the relevant interest in this topic, we are pleased to announce the second version of this Special Issue.

This Special Issue invites the submission of research papers or reviews focused on bioactive compounds from marine Streptomyces isolated by traditional methods or produced by the application of synthetic biology techniques, chemical modification from marine natural product lead compounds, and pharmacological research highlighting progress in the following topics: bioactivity screening; novel natural product discovery; structural characterization; genome mining; elucidation of biosynthetic pathways; genomics- and metabolomics-driven studies; chemical synthesis; and potential applications.

Prof. Dr. Jianhua Ju
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine streptomyces
  • natural products
  • structural characterization
  • bioactivities
  • genome mining
  • drug discovery
  • chemical modifications/chemical synthesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 4902 KiB  
Article
Saquayamycin B1 Suppresses Proliferation, Invasion, and Migration by Inhibiting PI3K/AKT Signaling Pathway in Human Colorectal Cancer Cells
by Jianjiang Li, Ningning Han, Hao Zhang, Xiaoyu Xie, Yaoyao Zhu, E Zhang, Jiahui Ma, Chuangeng Shang, Mengxiong Yin, Weidong Xie and Xia Li
Mar. Drugs 2022, 20(9), 570; https://doi.org/10.3390/md20090570 - 7 Sep 2022
Cited by 4 | Viewed by 2278
Abstract
Moromycin B (Mor B), saquayamycin B1 (Saq B1), saquayamycin B (Saq B), and landomycin N (Lan N), four angucyclines produced by the marine-derived actinomycete Streptomyces sp., are a class of polyketone compounds containing benzanthracene. Here, the structure–activity relationship of these [...] Read more.
Moromycin B (Mor B), saquayamycin B1 (Saq B1), saquayamycin B (Saq B), and landomycin N (Lan N), four angucyclines produced by the marine-derived actinomycete Streptomyces sp., are a class of polyketone compounds containing benzanthracene. Here, the structure–activity relationship of these four compounds was analyzed in human colorectal cancer (CRC) cells. Saq B1, which showed the strongest cytotoxicity with an IC50 of 0.18–0.84 µM for CRC cells in MTT assays, was employed to test underlying mechanisms of action in SW480 and SW620 cells (two invasive CRC cell lines). Our results showed that Saq B1 inhibited CRC cell proliferation in a dose- and time-dependent manner. Notably, lower cytotoxicity was measured in normal human hepatocyte cells (QSG-7701). Furthermore, we observed proapoptosis, antimigration, and anti-invasion activities of Saq B1 in CRC cells. At the same time, the protein and mRNA expression of important markers related to the epithelial–mesenchymal transition (EMT) and apoptosis changed, including N-cadherin, E-cadherin, and Bcl-2, in Saq B1-treated CRC cells. Surprisingly, the PI3K/AKT signaling pathway was shown to be involved in Saq B1-induced apoptosis, and in inhibiting invasion and migration. Computer docking models also suggested that Saq B1 might bind to PI3Kα. Collectively, these results indicate that Saq B1 effectively inhibited growth and decreased the motor ability of CRC cells by regulating the PI3K/AKT signaling pathway, which provides more possibilities for the development of drugs in the treatment of CRC. Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Streptomyces (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop